e20577 Background: Elderly patients are underrepresented in clinical trials, yet account for significant group with small cell lung cancer (SCLC). We examined if the age of the patients, <70yrs vs >70yrs, impacted outcome. Methods: SCLC pts were identified by searching the hospital cancer registry from 1999 to 2009. Pt characteristics, management and outcomes were collated by reviewing clinical records. Survival analysis was performed. Results: From 168 SCLC pts, 49 (27 males, 22 females) had limited stage (LS) and 113 (71 males, 42 females) extensive stage (ES) SCLC. LS cohort, 27 pts were <70yrs and 22 were >70yrs. The overall group survival was not statistically different, with median overall survival of 12.4 months for <70yrs and 7.8 months for >70yrs (p=0.064). However, 44 pts who had active treatment, including chemoradiotherapy, chemotherapy alone, radiotherapy alone, there was statistically improved survival between <70yrs vs >70yrs of 12.8 months vs 8.2 months (p=0.05). There was no significant difference in proportion of pts who received active treatment between the two groups (96.2% vs 95.4% p =0.882). The number of pts completing treatment was not statistically different between the two age groups (70.8% vs 54.5% p = 0.53) In the ES cohort, 45 pts were <70yrs and 68 were >70yrs. The overall group survival was significantly worse in the >70yrs with MOS 3.8 months for >70yrs and MOS 6.9 for <70yrs (p=0.0087). In pts who had active treatment, significantly higher proportion of pts <70yrs received active treatment, including chemoradiotherapy, chemotherapy alone and radiotherapy alone, (77% versus 69%, p= 0.015). In pts who had active treatment, the survival was not statistically different, MOS <70yrs 7.4 months vs >70yrs 5.9 months (p= 0.088). Significantly less pts >70yrs vs <70yrs completed treatment (20% versus 39% p = 0.032). Conclusions: In LS SCLC, comparing treated patients <70yrs vs >70yrs, patients >70yrs had reduced survival, this may be related to patient factors or tumour biology. In ES SCLC, comparing patients<70yrs vs >70yrs, patients >70yrs had worse survival overall, less likely to receive active treatment and less likely to complete treatment, again this may reflect a difference in patient factors or tumour biology.
Time-to-Event Analysis of Paclitaxel-Associated Peripheral Neuropathy in Advanced Non–Small-Cell Lung Cancer Highlighting Key Influential Treatment/Patient Factors
